Aimmune enrolls first patient in phase 2 trial of AR201 for egg allergy
Aimmune Therapeutics announced it has randomized its first patient in a phase 2 clinical trial of AR201 for treatment of egg allergy. AR201, an investigational biological drug for use in oral immunotherapy for egg allergy, is the second development program that Aimmune is advancing. August 21, 2019